Saturday , May 27 2017
Home / Technology & Devices

Technology & Devices

Shire’s Hemophilia Candidate Using Xenetic Technology Platform Fails in Phase 1/2 Trial

LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has received an update on the Phase 1/2 clinical study conducted by its partner Shire, evaluating …

Read More »

X-Chem and Vertex Enter Multi-Target Genetic Disease Partnership

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Under the terms of the agreement, X-Chem will apply its proprietary DEXTM libraries, which contain more than …

Read More »

Intellia Announces Progress with CRISPR Technology at the ASGCT Annual Meeting

WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, presented an update on its long-term mouse genome editing and delivery studies and shared new, first-time data in rat models demonstrating consistent dose-dependent …

Read More »

Veracyte Announces Next-Generation Afirma Test Can Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif., May 4, 2017 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced data from a pivotal clinical validation study of its Afirma Genomic Sequencing Classifier (GSC). The data suggest that the …

Read More »

Bluebird Bio Licenses Delivery Technology to Novartis for Development of CAR-T Therapies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG. “bluebird bio is a pioneer in the field of lentiviral vector-based cell and gene therapy, and our partnerships and licensing agreements have …

Read More »

New Imaging Method May Predict Immunotherapy Response Early

Bottom Line: A noninvasive PET imaging method that measures granzyme B, a protein released by immune cells to kill cancer cells, was able to distinguish mouse and human tumors that responded to immune checkpoint inhibitors from those that did not respond early in the course of treatment. Journal in Which …

Read More »

Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the prognostic accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in a cohort of patients with head and neck melanoma. Results demonstrated that the DecisionDx-Melanoma test accurately identifies …

Read More »

FDA Approves Novartis’ Rydapt for Treatment of Patients with Acute Myeloid Leukemia

SILVER SPRING, Md., April 28, 2017 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with …

Read More »

BD to Acquire Bard for $24 Billion

FRANKLIN LAKES, N.J. and MURRAY HILL, N.J., April 23, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a …

Read More »

Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …

Read More »